论文部分内容阅读
目的探究胸腺肽α-1辅助治疗哮喘-慢阻肺重叠综合征的临床效果。方法选取上高县翰堂卫生院2014年4月—2015年4月收治的哮喘-慢阻肺重叠综合征患者76例,随机分为对照组与观察组,各38例。对照组患者给予常规治疗,观察组在对照组基础上辅助应用胸腺肽α-1治疗。比较两组患者治疗前后动脉血氧分压(PaO_2)、第1秒用力呼气容积(FEV_1)、第1秒用力呼气容积占用力肺活量的百分比(FEV_1/FVC)。结果治疗前两组患者PaO_2、FEV_1及FEV_1/FVC比较,差异无统计学意义(P>0.05);治疗后观察组PaO_2、FEV_1及FEV_1/FVC高于对照组,差异有统计学意义(P<0.05)。结论胸腺肽α-1辅助治疗哮喘-慢阻肺重叠综合征的临床效果明显,可增强患者的免疫功能,有效改善患者的肺功能,使疾病得到有效控制,降低疾病发病率。
Objective To investigate the clinical effect of thymosin α-1 adjuvant therapy on asthma-COPD patients. Methods 76 patients with asthma-COPD patients admitted from April 2014 to April 2015 in Shantang Hospital of Shanggao County were randomly divided into control group and observation group, with 38 cases in each group. Patients in the control group were given routine treatment, and the observation group was assisted by thymosin α-1 on the basis of the control group. PaO2, FEV_1 and FEV 1 / FVC of the two groups were compared before and after treatment. Results There were no significant differences in PaO_2, FEV_1 and FEV_1 / FVC between the two groups before treatment (P> 0.05). After treatment, PaO_2, FEV_1 and FEV_1 / FVC in the observation group were significantly higher than those in the control group (P < 0.05). Conclusion Thymosin α-1 adjuvant treatment of asthma - COPD patients has obvious clinical effect, which can enhance the immune function, effectively improve the patient’s lung function, effectively control the disease and reduce the incidence of the disease.